Results 31 to 40 of about 3,441 (189)

HIV-1 Non Group-M Phenotypic Susceptibility to Ibalizumab. [PDF]

J Med Virol
ABSTRACT The study assessed the phenotypic susceptibility of non group‐M human immunodeficiency virus type 1 (HIV‐1/non‐M) clinical isolates to ibalizumab, the first‐in‐class long‐acting CD4‐directed post‐attachment inhibitor. Thirty isolates were tested: 1 HIV‐1/M (reference strain BRU.HXB2), 2 HIV‐1/N, 26 HIV‐1/O and 1 HIV‐1/P.
Poisson L, Hingrat QL, Lermechain F, Tombette F, Jullien H, Plantier JC, Alessandri-Gradt E.   +6 more
europepmc   +2 more sources

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development [PDF]

, 2004
The peptidic antiretroviral enfuvirtide (Fuzeon) is the first clinically approved antiviral fusion inhibitor and the first antiretroviral that must routinely be administered parenterally.
David A Cooper, Cooper, David A., Lange, Joep M. A., Joep MA Lange   +3 more
core   +1 more source

A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion. [PDF]

PLoS ONE, 2013
Fusion inhibitors are a class of antiretroviral drugs used to prevent entry of HIV into host cells. Many of the fusion inhibitors being developed, including the drug enfuvirtide, are peptides designed to competitively inhibit the viral fusion protein ...
Matthew P Wood, Amy L Cole, Piotr Ruchala, Alan J Waring, Lisa C Rohan, Preston Marx, Patrick M Tarwater, Phalguni Gupta, Alexander M Cole   +8 more
doaj   +1 more source

HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay. [PDF]

PLoS ONE, 2018
Human Immunodeficiency Virus-1 (HIV-1) entry is dependent on the envelope glycoprotein (Env) that is present on the virion and facilitates fusion between the envelope and the cellular membrane.
Edward Yang, Matthew R Gardner, Amber S Zhou, Michael Farzan, Ann M Arvin, Stefan L Oliver   +5 more
doaj   +1 more source

Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide [PDF]

, 2011
The data on the use of tipranavir and enfuvirtide in pregnancy are very limited. We performed a pharmacokinetic profile in a pregnant woman with multidrug-resistant HIV-1 infection at 37 weeks gestation.
K Weizsaecker, M Kurowski, C Feiterna-Sperling, B Hoffmeister, D Schürmann   +4 more
core   +1 more source

Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses

Human Vaccines & Immunotherapeutics, 2017
Background: Genetic immunization is expected to induce the expression of antigens in a native form. The encoded peptide epitopes are presented on endogenous MHC molecules, mimicking antigen presentation during a viral infection.
S. Stenler, K. E. Lundin, L. Hansen, S. Petkov, N. Mozafari, M. Isaguliants, P. Blomberg, C. I. E. Smith, D. M. Goldenberg, C.-H. Chang, K. Ljungberg, J. Hinkula, B. Wahren   +12 more
doaj   +1 more source

Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor [PDF]

, 2008
We present a model of the pharmacokinetics of enfuvirtide, a potent inhibitor of the fusion of human immunodeficiency virus type 1 (HIV-1) with target cells.
Mohanty, Utkala, Utkala Mohanty, Narendra M. Dixit, Dixit, Narendra M.   +3 more
core   +1 more source

Immunostimulatory effects on THP-1 cells by peptide or protein pharmaceuticals associated with injection site reactions

Journal of Immunotoxicology, 2020
Injection site reaction (ISR) is a common side-effect associated with the use of peptide or protein pharmaceuticals. These types of pharmaceuticals-induced activation of antigen-presenting cells is assumed to be a key step in the pathogenesis of immune ...
Eri Hamamura-Yasuno, Tetsuo Aida, Yoshimi Tsuchiya, Kazuhiko Mori   +3 more
doaj   +1 more source

Functional analyses reveal extensive RRE plasticity in primary HIV-1 sequences selected under selective pressure. [PDF]

PLoS ONE, 2014
BackgroundHIV-1 Rev response element (RRE) is a functional region of viral RNA lying immediately downstream to the junction of gp120 and gp41 in the env coding sequence.
Francesc Cunyat, Nancy Beerens, Elisabet García, Bonaventura Clotet, Jørgen Kjems, Cecilia Cabrera   +5 more
doaj   +1 more source

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice

Vaccines, 2022
In this study, the HIV-1 P18I10 CTL peptide derived from the V3 loop of HIV-1 gp120 and the T20 anti-fusion peptide of HIV-1 gp41 were inserted into the HPV16 L1 capsid protein to construct chimeric HPV:HIV (L1:P18I10 and L1:T20) VLPs by using the ...
Chun-Wei Chen, Narcís Saubi, Athina Kilpeläinen, Joan Joseph-Munné   +3 more
doaj   +1 more source